trending Market Intelligence /marketintelligence/en/news-insights/trending/G_rI9NyVwE4SRBNSscxMcw2 content esgSubNav
In This List

Shandong Luoxin Pharma shareholders approve delisting of shares

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Shandong Luoxin Pharma shareholders approve delisting of shares

Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. shareholders approved the resolution for the proposed delisting of the company's H shares from The Stock Exchange of Hong Kong Ltd.

The H shares can be traded until June 5. Trading will be suspended June 6, and the shares will be delisted June 16.

Additionally, a voluntary conditional offer by Giant Star Global (HK) Ltd. and Ally Bridge Flagship LX (HK) Ltd. for all the issued H shares became unconditional on May 29. The offer will close June 26.